Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "Glenmark"

100 News Found

Indian Pharma Market slips for third month in a row: Anand Rathi
News | May 10, 2022

Indian Pharma Market slips for third month in a row: Anand Rathi

According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)


Cipla bags Pharma Leader of the Year award
News | April 28, 2022

Cipla bags Pharma Leader of the Year award

Glenmark Pharmaceuticals won Innovation of the Year award


Thirty five generic manufacturers sign agreements with MPP for Paxlovid
News | March 18, 2022

Thirty five generic manufacturers sign agreements with MPP for Paxlovid

The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris


North America accounts for 50 % of generic pharma market
News | December 03, 2021

North America accounts for 50 % of generic pharma market

Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively


Fifty-five manufacturers selected for Pharma PLI sector
News | November 27, 2021

Fifty-five manufacturers selected for Pharma PLI sector

The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme


Indian pharma CEOs bet big on innovation to achieve US $130 bn
News | November 23, 2021

Indian pharma CEOs bet big on innovation to achieve US $130 bn

While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report


Temasek to buy a stake in Integrace
Startup | October 05, 2021

Temasek to buy a stake in Integrace

The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition


Indian Pharmaceutical Market grew by 17.7 per cent in August
News | September 07, 2021

Indian Pharmaceutical Market grew by 17.7 per cent in August

Ind-Ra expects IPM revenue to grow over 12% YoY in FY22


Industry-academia collaboration key to strengthening pharma R&D
News | March 04, 2021

Industry-academia collaboration key to strengthening pharma R&D

The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .